Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 17, Number 2, February 2026, pages 54-61

Long-Term Disease-Free Survival After Sorafenib-Combined Chemotherapy for Refractory Metastatic Testicular Germ Cell Tumor: A Five-Year Follow-Up

Figures

↓  Figure 1. Tumor marker levels (hCG, AFP, LDH) and patient treatment timeline. The graph illustrates the patient’s tumor marker levels over time, corresponding to various stages of treatment and clinical response. The timeline at the bottom details the specific therapies administered, including orchiectomy, several chemotherapy regimens, targeted therapy, and radiotherapy. The markers track the patient’s condition from initial partial response and relapse to a final clinical cure. hCG: human chorionic gonadotropin; AFP: alpha-fetoprotein; LDH: lactate dehydrogenase; BEP: bleomycin + etoposide + cisplatin; GEMOX: gemcitabine plus oxaliplatin; PD: progressive disease; PD-L1: programmed cell death ligand 1; PR: partial response; CR: complete response.
Figure 1.
↓  Figure 2. Imaging changes throughout the entire treatment and follow-up process. (a) CT-guided biopsy in 2018 and 2019. (b, c) Imaging changes in the retroperitoneum, lumbar vertebral bodies and bilateral lungs throughout the entire treatment and follow-up process. The oval circles marked the metastatic lesions in the retroperitoneal lymph nodes and lumbar vertebral bodies, and the arrows indicated the bilateral lung lesions. Treatment and follow-up time points were shown on the left. (d) Changes shown on brain MRI of metastatic lesions in the left frontal lobe (arrow) throughout the entire treatment and follow-up process. The treatment and follow-up time points were shown below. CT: computed tomography; MRI: magnetic resonance imaging; PD-L1: programmed death-ligand 1; BEP: bleomycin + etoposide + cisplatin.
Figure 2.